Antibodies in Repeated Influenza Vaccination (ARIVA) Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Influenza specific Antibody Responses
研究概览
简要总结
Viruses with high mutation rates, such influenza or HIV, pose a major challenge for vaccine design. The current influenza vaccination strategy of yearly vaccination with adapted strains aims to maximally diversify the antibody immune response to prevent viral escape. There is, however, growing evidence, that repeated vaccination with very similar viral proteins might limit, instead of broaden, diversification and thereby reduce vaccine efficacy.
The ARIVA Study prospectively studies the immunological impact of repeated influenza vaccination on viral variant recognition and antibody responses in healthy subjects cross-sectionally and over three consecutive vaccination seasons.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •influenza vaccination (QIIV) independent of the study
- •age >18 yo
排除标准
- •no vaccination
- •current acute illness
结局指标
主要结局
Influenza specific Antibody Responses
时间窗: Change between baseline and 28 days post-vaccination will be compared
Hemagglutination titers against different H3N2 Influenza strains will be measured and compared between study subjects stratified by number of previous vaccinations
次要结局
- Plasmablast generation(Day 7 post-vaccination)
- BCR Repertoire composition(Cross sectional comparison of the BCR repertoire characteristics day 0 and day 28)
研究者
Christoph Berger
Principal Investigator
University Hospital, Basel, Switzerland